{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:17:16Z","timestamp":1753881436837,"version":"3.41.2"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,12,16]]},"abstract":"<jats:p>\n            Given that it is unlikely that randomized clinical trials will yield answers for treating the most challenging bacteremic infections caused by methicillin-resistant\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            , clinicians, microbiologists, and pharmacists will have to cooperate to discover novel ways to select successful individualized antimicrobial therapy for these patients. An example of such a strategy was demonstrated in the identification and utilization of imipenem\/cilastatin plus fosfomycin to treat a particularly recalcitrant MRSA bacteremia and spinal abscess.\n          <\/jats:p>","DOI":"10.1128\/aac.02039-20","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T14:51:30Z","timestamp":1601909490000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Case Commentary: Imipenem\/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant\n            <i>Staphylococcus aureus<\/i>\n            Infection: a Novel Combination Therapy"],"prefix":"10.1128","volume":"65","author":[{"given":"George","family":"Sakoulas","sequence":"first","affiliation":[{"name":"Division of Host-Microbe Systems &amp; Therapeutics, Center for Immunity, Infection &amp; Inflammation, Collaborative to Halt Antimicrobial Resistant Microbes, University of California\u2013San Diego School of Medicine, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01746-20"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1581-1585.2006"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071151"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz538"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02483-18"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku236"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.631"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir340"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06449-11"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006723"},{"key":"e_1_3_1_12_2","volume-title":"IDWeek 2018, San Francisco, CA, USA","author":"Pujol M","year":"2018","unstructured":"Pujol M, Miro JM, Shah A, . 2018. Daptomycin plus fosfomycin versus daptomycin monotherapy for methicillin-resistant Staphylococcus aureus bacteremia. A multicenter, randomized, clinical trial, abstr LB3. In IDWeek 2018, San Francisco, CA, USA. Infectious Diseases Society of America, Arlington, VA."},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04141-14"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.0103"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01877-16"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.105864"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1911"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1121-9"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.040"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02039-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02039-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:53:43Z","timestamp":1645480423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02039-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,16]]}},"alternative-id":["10.1128\/AAC.02039-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.02039-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"2020-12-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02039-20"}}